Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 605 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 Elliot Colburn MP: Why Cancer Research UK’s Manifesto for Cancer Research... May 9, 2023 Better together: improving brain tumour treatment February 13, 2023 EMA Recommends Extension of Indications for Datopotamab Deruxtecan August 21, 2026 Load more HOT NEWS COVID-19 Vaccine Myth Busters Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... Fructose Fuels Cancer Growth Indirectly, Lab Study Finds Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients...
